Cartesian Therapeutics, Inc.
RNAC
$8.63
-$0.08-0.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -91.76% | 109.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -91.76% | 109.51% | |||
| Cost of Revenue | 32.50% | 6.43% | |||
| Gross Profit | -41.06% | -2.94% | |||
| SG&A Expenses | -13.21% | 6.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.13% | 6.36% | |||
| Operating Income | -20.78% | -4.14% | |||
| Income Before Tax | 61.50% | -183.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 57.68% | -157.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 57.68% | -157.86% | |||
| EBIT | -20.78% | -4.14% | |||
| EBITDA | -21.34% | -4.26% | |||
| EPS Basic | 59.01% | -157.82% | |||
| Normalized Basic EPS | -23.09% | -5.08% | |||
| EPS Diluted | 59.05% | -158.06% | |||
| Normalized Diluted EPS | -23.09% | -5.08% | |||
| Average Basic Shares Outstanding | 3.26% | 0.01% | |||
| Average Diluted Shares Outstanding | 3.26% | 0.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||